Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study-Reference-Cited by-同舟云学术

Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study

Published:2020-12-08 Issue:3 Volume:28 Page:280-287
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Uemura Hirotsugu¹,Arai Gaku²,Uemura Hiroji³,Suzuki Hiroyoshi⁴,Iijima Kazuyoshi⁵,Nishimura Kazuo⁶,Fujii Koji⁷,Hatayama Tomoyoshi⁷,Aoyama Junya⁷,Deprince Kris⁸,Lopez‐Gitlitz Angela⁹,McCarthy Sharon¹⁰,Larsen Julie S⁹,Li Jinhui¹¹,Chi Kim N¹²

Affiliation:

1. Department of Urology Kindai University Hospital Osakasayama OsakaJapan

2. Department of Urology Dokkyo Medical University Saitama Medical Center Koshigaya SaitamaJapan

3. Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama KanagawaJapan

4. Department of Urology Toho University Sakura Medical Center Sakura ChibaJapan

5. Department of Urology Nagano Municipal Hospital NaganoJapan

6. Department of Urology Osaka International Cancer Institute OsakaJapan

7. Janssen Pharmaceutical K.K. Tokyo Japan

8. Janssen Research and Development Beerse Belgium

9. Janssen Research and Development Los Angeles CaliforniaUSA

10. Janssen Research and Development Raritan New JerseyUSA

11. Janssen Research and Development San Diego California USA